Evidence has been provided showing enhanced activity of the histone deacetylase (HDAC)-inhibitor valproic acid (VPA) combined with low dosed interferon alpha (IFNα), compared to monotherapy in PCa cells 9. The gene discussed is HDAC9; the disease is posterior cortical atrophy.